POSITRON EMISSION COMPOSITIONS CONTAINING INORGANIC PARTICLES, AND USE THEREOF IN MEDICINE, PARTICULARLY FOR DIAGNOSTIC PROCEDURES Russian patent published in 2012 - IPC A61K51/12 A61K101/02 A61K103/34 A61K33/08 A61K33/10 A61K33/26 A61K33/42 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical agent to be used as a diagnostic agent containing an inorganic matrix in the form of particles of amorphous or mixed amorphous and crystalline structures which contains a portion of positron emission nuclides in addition to natural isotope distribution of structural type-forming elements anions and cations. The inorganic matrix is represented by topaz (Al₂F₂)[SiO₄], chiolite Na[Al₃F₄], wavellite Al₃(PO₄)₂(OH, F)₂, calcium carbonate CaCO₃, maghemite -Fe₂O₃, zeolites of general formula Mn[(AlO₂)x(SiO₂)_y] (M = metal), magnetic iron Fe₃O₄, barium sulphate BaSO₄, gallium phosphate GaPO₄, apatite or fluorohydroxyapatite Ca₅(PO₄)₃(OH, F)=3Ca₃(PO₄)₂*Ca(OH, F)₂ and fluorite CaF₂. The positron emission nuclides are specified in [15]O, [30]P, [13]N, [65]Ga, [11]C, [131]Ba, [26]A1, [68]Ga and [18]F, and their number in the inorganic matrix makes more than 1. The invention also refers to a method for preparing said pharmaceutical agent involving mixing two solutions of soluble salts and depositing them wherein one salt is saturated by positron emission nuclides, while the cations of one salt are deposited with the cations of the other salt to form the inorganic matrix. The invention also refers to a pharmaceutical composition used for the purpose of diagnostic visualisation wherein more then 0.001% of particles contained in the composition represent said inorganic matrix.

EFFECT: invention provides simplified production of specific particles of the more prolonged applicability for the use which are applicable for diagnostic visualisation.

9 cl, 6 dwg, 2 tbl, 3 ex